Kennedy Ferruggia, Associate Editor

Research reveals semaglutide's potential to reduce cocaine-seeking behavior in rats, suggesting a promising avenue for treating cocaine dependency in humans.

Researchers uncover a brain circuit linking stress to increased blood glucose, revealing insights into stress's role in type 2 diabetes (T2D) development.

The FDA approves a groundbreaking gemcitabine system, offering new hope for patients with BCG-unresponsive bladder cancer.

MM120 shows promise in treating generalized anxiety disorder, demonstrating significant symptom relief and a potential shift in psychiatric treatment approaches.

FDA expands Vonvendi use for von Willebrand disease (VWD), enhancing treatment options for adults and children to manage bleeding effectively.

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

Individuals with learning disabilities face a heightened risk of severe type 2 diabetes (T2D), leading to increased mortality despite better glycemic control.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

Research reveals associations between body composition, fitness, and mental health in children, highlighting the impact of obesity on anxiety and depression.

A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.

Abemaciclib significantly enhances overall survival in high-risk HR+, HER2- early breast cancer, establishing a new standard of care.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

An international BMJ panel recommended broader use of SGLT-2 inhibitors and GLP-1 receptor agonists.

The FDA has approved a ready-to-use long-acting injectable formulation that is administered every 3 months as a treatment for advanced prostate cancer.

Employers are facing higher costs and employees higher premiums as 340B’s growth drives lost rebates and rising drug prices.

An immunomodulatory nanoparticle called Agg-CLNP has been shown to effectively prevent disease onset for rheumatoid arthritis (RA).

Generic liraglutide injection is the first GLP-1 indicated for weight loss.

COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.

Orforglipron is an effective treatment, leading to significant body weight reduction and improved glycemic control.

Increasing dietary potassium, such as from bananas, may lower blood pressure more effectively than reducing sodium alone.

The sensor detects acetone levels in the breath to indicate diabetes.

Expert emphasizes the need for stronger transparency and patient definitions in the 340B program.

A novel shingles vaccine candidate demonstrated positive top-line results of antibody and CD4⁺ T-cell vaccine responses.

A better understanding of the activation of amylin receptors is a step forward for developing new drugs.

RSV causes a significant burden of acute respiratory infections in older adults.

Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).

Individuals with bipolar disorder are at nearly a 2-fold higher risk of heart failure, which is marked as the main cause of premature cardiovascular mortality.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

The oral glucagon-like peptide agonist-1 met its primary end point and all secondary end points in a randomized, double-blind, placebo-controlled clinical trial for weight management.